Vanguard Group Inc. Raises Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Vanguard Group Inc. boosted its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,743,482 shares of the company's stock after purchasing an additional 708,817 shares during the quarter. Vanguard Group Inc. owned about 5.07% of Scholar Rock worth $205,013,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SRRK. GAMMA Investing LLC raised its holdings in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after buying an additional 269 shares during the last quarter. Quarry LP increased its position in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company's stock valued at $36,000 after acquiring an additional 4,373 shares during the period. Global Retirement Partners LLC raised its stake in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after acquiring an additional 1,031 shares during the period. Finally, Amalgamated Bank grew its stake in shares of Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of Scholar Rock stock traded down $0.75 during trading on Thursday, reaching $26.31. The company's stock had a trading volume of 1,377,148 shares, compared to its average volume of 1,210,284. The business has a 50 day moving average price of $34.45 and a 200-day moving average price of $34.37. The company has a market capitalization of $2.49 billion, a P/E ratio of -11.20 and a beta of 0.56. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98.

Analysts Set New Price Targets

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock presently has a consensus rating of "Buy" and a consensus target price of $42.67.

Insiders Place Their Bets

In other news, insider Jing L. Marantz sold 5,655 shares of Scholar Rock stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares in the company, valued at approximately $2,970,240. This trade represents a 7.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jay T. Backstrom sold 22,308 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $986,013.60. Following the completion of the sale, the chief executive officer now owns 330,363 shares in the company, valued at approximately $14,602,044.60. This represents a 6.33 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 299,772 shares of company stock worth $11,245,798. Corporate insiders own 19.20% of the company's stock.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.